AbbVie Inc. (BCBA: ABBV)

Market Cap	317.29T
Revenue (ttm)	53.86T
Net Income (ttm)	4.93T
Shares Out	n/a
EPS (ttm)	2,783.24
PE Ratio	64.39
Forward PE	n/a
Dividend	350.87 (1.75%)
Ex-Dividend Date	Oct 15, 2024

Volume	102
Open	19,825
Previous Close	19,900
Day's Range	19,525 - 20,025
52-Week Range	11,997 - 26,225
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 31, 2025

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 50,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.

Financial numbers in USD